Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Breast 2 afatinib in metastatic HER2-positive breast cancer after failure of HER2-targeted adjuvant/neoadjuvant therapy
2010-021945-29Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in breast cancer, sponsored by Boehringer Ingelheim. Primary endpoint: Objective response (OR) by RECIST 1.1. Started Oct 2010; status: completed.
02
Drugs
afatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-021945-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021945-29.